Cartalax: A Tripeptide Bioregulator Studied in Connective and Renal Tissue

Research summary. Cartalax (Ala-Glu-Asp, AED) is a synthetic tripeptide member of the Khavinson short-peptide bioregulator family. It is one of the shorter members of the family — composed of just three amino acids — and is reported in the source literature to have effects on fibroblast biology, extracellular matrix remodelling, and cellular senescence markers. Reported research interest has clustered around skin, cartilage-relevant fibroblast biology, and renal tissue.

Molecular profile

• Sequence: Ala-Glu-Asp (AED)
• Molecular formula: C₁₂H₁₉N₃O₈
• Molecular weight: ~333.3 g/mol
• PubChem CID: 87815447
• Synonyms: T-31, Alanyl-glutamyl-aspartic acid
• Class: Short peptide bioregulator (Khavinson peptides)

Mechanism of action

The proposed mechanism is consistent with the broader bioregulator framework: penetration of the cell and nuclear membranes by the unmodified tripeptide, followed by direct interaction with chromatin to modulate tissue-specific transcriptional programmes. For Cartalax, the reported targets include:

• Fibroblast proliferation and matrix turnover. Cartalax has been linked to upregulation of proliferation markers (Ki-67, CD98hc) in cultured fibroblasts and downregulation of MMP-9, with implications for ECM remodelling.
• Cellular senescence and apoptotic signalling. Reported reductions in p16, p21, and p53 expression, alongside increases in SIRT-6, position the peptide as a candidate modulator of senescence-associated phenotypes.
• Gerogene expression panel. Modulation of expression of IGF1, FOXO1, TERT, TNKS2, and NF-κB has been reported in fibroblast and renal-cell preparations from aged animals.

Preclinical research highlights

Skin and dermal fibroblasts. A number of cell-culture studies have reported that Cartalax exposure increases proliferation and migration of dermal fibroblasts and supports extracellular matrix remodelling, with downregulation of MMP-9 and upregulation of markers typically reduced with age.

Renal tissue. Cartalax was originally identified within polypeptide isolates from calf kidneys that demonstrated effects on aged rodent renal tissue. Follow-up work attributed proliferation-supporting and senescence-attenuating effects in renal-cell preparations specifically to this tripeptide, with reported elevation of SIRT-6 and reduction of p16/p21/p53 in cultured cells from aged animals.

Cartilage-relevant fibroblast biology. Direct studies of articular cartilage with Cartalax are limited. The interest in cartilage applications derives from the peptide's documented effects on fibroblast signalling and ECM turnover, which by extension may influence chondrocyte and matrix biology — a hypothesis that has not been directly tested with the rigour applied to skin or renal models.

Antioxidant and immunomodulatory effects. Cell-based studies have reported antioxidant activity of Cartalax in connective-tissue preparations, alongside modulation of inflammatory cytokine expression in fibroblast cultures.

Limitations of the current evidence

Cartalax shares the methodological caveats common to the Khavinson bioregulator family:

• Most of the supporting literature originates from a single research programme.
• The proposed mechanism — direct DNA or chromatin interaction by an unmodified tripeptide — has not been independently confirmed at the molecular-structural level.
• The body of work is heavily oriented toward cell-culture and rodent-tissue endpoints rather than functional in-vivo outcomes in independent laboratories.
• No registered Phase 2 or Phase 3 clinical trials of Cartalax appear in the major Western trial registries at the time of writing.

These caveats do not invalidate the reported observations but do warrant explicit acknowledgement when designing further studies or evaluating claims.

Position within the bioregulator family

Cartalax differs from many bioregulator-family peptides in two respects worth noting. First, it is a tripeptide rather than a tetrapeptide, which makes it among the shortest members of the family. Second, its reported tissue tropism is broader and less anatomically specific than peptides like Bronchogen (lung), Cardiogen (heart), or Cortagen (cortex) — its effects appear to centre on fibroblast and connective-tissue biology generally, rather than on a single named organ. This has positioned it within the bioregulator literature as a candidate "geroprotective" peptide rather than a tissue-targeted one.

Current research status

Cartalax remains an investigational research peptide. It is not an approved therapeutic agent. Its principal roles in current research are as a reference compound in the bioregulator family, a tool for studying fibroblast senescence and proliferation, and a candidate molecule in geroprotective research within the Khavinson framework.

Key takeaways for researchers

• Cartalax is a tripeptide (Ala-Glu-Asp) bioregulator from the Khavinson short-peptide programme.
• Its reported effects centre on fibroblast biology, ECM remodelling, and modulation of senescence-associated markers (p16, p21, p53, SIRT-6).
• Originally identified in calf-kidney polypeptide isolates, it has been studied across dermal, renal, and connective-tissue cell-culture systems.
• Independent replication of mechanistic claims remains limited.
• Cartalax is not an approved therapeutic.

References

1. Khavinson VK, Linkova NS, Tarnovskaya SI, et al. Short peptides stimulate cell regeneration: from theory to clinical practice. Bulletin of Experimental Biology and Medicine. 2014;156(3):283–289.
2. Lin'kova NS, Drobintseva AO, Orlova OA, et al. Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine. 2016;161(1):175–178.

---

This article is provided for educational and research purposes only. Cartalax is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.